Ideas For Now-

Wait-- CONFIRMATION!


Opko Investigating False Positive Covid-19 Tests From NFL Teams
By
Bailey Lipschultz<--- Thnak God I don't have this name!
August 24, 2020, 10:26 AM EDT

Opko Health Inc. is investigating several likely false positive Covid-19 tests results from National Football League players and personnel that affected multiple teams.

The spike in positive results was likely caused by “an isolated contamination during test preparation in the New Jersey laboratory,” the Miami-based company’s BioReference Laboratories unit said in a statement. All of the people affected have since been confirmed to not have the virus, the company said.

Bio-Reference Laboratories, Inc.
Clinical laboratory company
upload_2020-8-24_12-5-6.jpeg
Description OPKO BABY!!! Get em Van!!!

Founded:1981
Subsidiaries:GeneDx,GenPath Diagnostics,MORE
Parent organization:OPKO Health<-------------------
 
What do you do when you have two different ratings from analysts buy and hold? But BOTH have the same price target??? Either that's a weak buy or a weak sell....

The stock Orasure currently $14 with $18 price targets... and two different opinions.

OraSure initiated with a Buy at Citi 08/10 OSUR Citi analyst Patrick Donnelly initiated coverage of OraSure with a Buy rating and $18 price target. Near-term catalysts include the upcoming COVID-19 antigen self-testing launch in Q4 and incremental demand for the company's molecular collection products tied to multiple third-party EUA approved saliva based COVID-19 PCR tests, Donnelly tells investors. The analyst also believes improving fundamentals in the base business should support a growth acceleration ex-COVID.
Show Related Items >> OraSure initiated with a Neutral at JPMorgan 08/10 OSUR JPMorgan analyst Tycho Peterson initiated coverage of OraSure with a Neutral rating and $18 price target. The analyst said the base business has potential tailwinds from COVID-19 Dx solutions and recent acquisitions in the DNA Genotek business could offset consumer genomics market weakness, but these opportunities are reflected in valuation.

I guess I'm an optimist but barring outright failure here, it looks lke even in a down scenario the co is stil worth $3 more than today. ~si
 
Van GWPH tossed in a lousy earnings report and that analyst changed their tune-- New Traget $155.

GW Pharmaceuticals reports Q2 EPS (2c) vs. 21 a year ago » 08/10 GWPH On August 6, GW… GW Pharmaceuticals price target lowered to $155 from $160 at Guggenheim 08/10 GWPH Guggenheim analyst Yatin Suneja lowered the firm's price target on GW Pharmaceuticals to $155 from $160 and keeps a Buy rating on the shares following last week's Q2 earnings report. The analyst sees modest q/q growth in 2H20.

Lets take the lowest target $140-- You're $106 now... I'd say it's a buy for IRA account. You need to hold about 3/4 a year at least but the return should be there.
 
stonedinvestor said:
Van GWPH tossed in a lousy earnings report and that analyst changed their tune-- New Traget $155.

GW Pharmaceuticals reports Q2 EPS (2c) vs. 21 a year ago » 08/10 GWPH On August 6, GW… GW Pharmaceuticals price target lowered to $155 from $160 at Guggenheim 08/10 GWPH Guggenheim analyst Yatin Suneja lowered the firm's price target on GW Pharmaceuticals to $155 from $160 and keeps a Buy rating on the shares following last week's Q2 earnings report. The analyst sees modest q/q growth in 2H20.

Lets take the lowest target $140-- You're $106 now... I'd say it's a buy for IRA account. You need to hold about 3/4 a year at least but the return should be there.
More...
$87 and I'll buy it.
 
vanzandt said:
$87 and I'll buy it.
More...
Stoney, I know tech is not your thing. But did you happen to notice that aside from a few biggies, the high flying tech stocks were red today?

I know this thread has morphed into the high % gainers, but that game won't last. Time to focus on the steady eddies I think. But I'll throw a wild one out there, but we need to wait until it dips below $25. Then put it in granny's portfolio. Slack. $WORK. Earnings are 9/3.
If it flatlines near $26 and all things stay equal, that'll work too.

Its a good stock, but its crowded. One more big flush and then up it goes.
 
Last edited:
TSLA, as soon as it makes another dip. It is starting to do that, now. One more day, two at the most, and the bird is done, ready to carve. Once it tags the lower Bollinger limit, you know it is gonna soar for about 8 days and give up 5% per day average, then dip and do it again. It's driving the whole Nasdaq, I think.
 
Just saying!->

GAP UPGRADED TO BUY ON 'BIG UPSIDE' POTENTIAL: Citi analyst Paul Lejuez upgraded Gap (GPS) to Buy from Neutral with a doubled price target of $24, up from $12. The company's ending of the planned Old Navy spinoff could imply its board is willing to take on corporate actions to unlock shareholder value, Lejuez tells investors in a research note. Given the "favorable positioning" of athletic/casual retailers in a post-Covid world, Gap's Athleta brand "stands out as having value that may not be getting recognized by the market," says the analyst. At the midpoint of his valuation estimates, Lejuez estimates Athleta is worth $3.6BN on a standalone basis or in a sale. With Gap's current enterprise value at just $6.5B, a sum-of-the-parts analysis implies "big upside," says the analyst.

 
Just saying!->

Ally Lending partners with Mastercard's Vyze 09:34 ALLY Ally Lending (ALLY) announced its partnership with Vyze, Mastercard's (MA) alternative financing platform for retailers. Ally's entrance into point-of-sale retail financing builds on its deep experience and rapidly growing footprint in healthcare and home improvement lending. Ally Lending will serve as the first installment loan lender on the Vyze platform, giving thousands of retail merchants access to a financially stable lender for higher-ticket sale options.
 
is it slack or work? Confusing and what about Yac?-- They are funded by Slack Funds do you get a p[lay on slack funds when you buy slack or have they parceled out that growth> ?

YAK launched last year has raised new money from the Slack Fund as it continues to gain ground among companies looking to give their employees new communication tools for remote working.

Developed by the digital agency SoFriendly, Yac's digital voice messaging service won the startup competition at the event and attracted the interest of Boost VC and its founder, the third-generation venture capitalist Adam Draper.

Officially launched in March and had 900 teams sign up within the first week. The company's product now includes one-to-many messaging,Slack integration and an improved desktop app. It also managed to attract the attention of the Slack Fund.

Slack. $WORK. Earnings are 9/3.

 
You must log in or register to reply here.
Back
Top